Raymond James initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $65 price target The company’s “differentiated” G-protein coupled receptors discovery platform has positioned with a potential best-in-class relaxin mimetic for the treatment of group two pulmonary hypertension and possibly other cardiovascular conditions, the analyst tells investors in a research note. The firm says Tectonic’s approach has been somewhat validated by Novartis (NVS).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECX:
- Tectonic Therapeutic Inc. Faces Challenges with Australian Subsidiary Amid Regulatory and Operational Risks
- Tectonic Therapeutic price target raised to $79 from $55 at Wells Fargo
- Tectonic Therapeutic Inc. Reports Q3 2024 Results
- Tectonic Therapeutic price target raised to $69 from $49 at Leerink
- Tectonic Therapeutic reports Q3 EPS ($1.20), consensus (82c)